Cytek Biosciences, Inc. (CTKB) Cash Flow Statement
Cytek Biosciences, Inc. (CTKB) generated -$6.0M of operating cash flow over the twelve months to 2026-06-30, spent $6.0M on capital expenditure and had free cash flow of -$12.1M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CTKBCytek Biosciences, Inc.Follow CTKB — free
—
Price chart with a free account
- Market cap
- 726.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 4.6 | -12.2 | 5.3 | 25.4 | -4.7 | -6.0 | |
| Capital expenditure | 4.4 | 9.7 | 4.6 | 3.5 | 4.1 | -6.0 | |
| Free cash flow | 0.3 | -22.0 | 0.6 | 21.9 | -8.8 | -12.1 | |
| Share repurchases | — | — | 44.2 | 21.6 | 15.1 | — | |
| Stock-based compensation | 6.6 | 16.6 | 22.0 | 26.8 | 24.6 | — |
USD millions · SEC XBRL
Cytek Biosciences, Inc. — questions
- What is Cytek Biosciences, Inc.'s operating cash flow?
- -$6.0M over the twelve months to 2026-06-30.
- How much does Cytek Biosciences, Inc. spend on capital expenditure?
- $6.0M over the twelve months to 2026-06-30.
- What is Cytek Biosciences, Inc.'s free cash flow?
- -$12.1M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Cytek Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.